The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

That said, the financial results of both Apple and Amazon had some weaknesses under the hood. Apple's Services division, ...

Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

Roche seeks US tariff relief in direct talks ... first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesity and type 2 diabetes.

This report is from today’s TNC’s Daily Open, our international markets update. TNC Daily Open keeps investors informed on everything they need to know, no matter where they are. Together with ...

Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

Roche has picked up a CE Mark approval in the EU for an artificial intelligence algorithm that can help doctors decide whether patients presenting with acute chest pain are having a heart attack.

Executives at Swiss-based Roche predict the drug maker is better off than other pharmaceutical companies as it had shifted inventories to prepare for a volatile year ahead and already relies ...